Padala, S. A. et al. Epidemiology of renal cell carcinoma. World J. Oncol. 11, 79–87 (2020).
Ljungberg, B. et al. European association of urology guidelines on renal cell carcinoma: The 2022 update. Eur. Urol. 82, 399–410 (2022).
Hemminki, O. et al. Treatment of advanced renal cell carcinoma: Immunotherapies have demonstrated overall survival benefits while targeted therapies have not. Eur. Urol. Open Sci. 22, 61–73 (2020).
Pinto, P. C. The potential impact of new drug and therapeutic modalities on drug resistance to renal cell carcinoma. Anticancer Res. 43, 983–991 (2023).
Zhan, X. et al. Trends in cause of death among patients with renal cell carcinoma in the United States: A SEER-based study. BMC Public Health 23, 770 (2023).
Pinto, P. C., Rönnau, C., Burchardt, M. & Wolff, I. Kidney cancer and chronic kidney disease: Too close for comfort. Biomedicines 9, 1761 (2021).
Kim, H. et al. Loss of Von Hippel-Lindau (VHL) tumor suppressor gene function: VHL–HIF pathway and advances in treatments for metastatic renal cell carcinoma (RCC). Int. J. Mol. Sci. 22, 9795 (2021).
Eckardt, K. U. et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int. 68, 46–51 (2005).
Bianchi, C. et al. The glucose and lipid metabolism reprogramming is gradedependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget 8, 113502–113515 (2017).
Lucarelli, G. et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev. Mol. Diagn. 19, 397–407 (2019).
Lucarelli, G. et al. MUC1 tissue expression and its soluble form CA15-3 identify a clear cell renal cell carcinoma with distinct metabolic profile and poor clinical outcome. Int. J. Mol. Sci. 23, 13968 (2022).
di Meo, N. A. et al. Renal cell carcinoma as a metabolic disease: An update on main pathways, potential biomarkers, and therapeutic targets. Int. J. Mol. Sci. 23, 14360 (2022).
Lucarelli, G. et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget 6, 13371–13386 (2015).
Ragone, R. et al. Renal cell carcinoma: A study through NMR-based metabolomics combined with transcriptomics. Diseases 4, 7 (2016).
Lucarelli, G. et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging 10, 3957–3985 (2018).
Bombelli, S. et al. 36-kDa annexin A3 isoform negatively modulates lipid storage in clear cell renal cell carcinoma cells. Am. J. Pathol. 190, 2317–2326 (2020).
di Meo, N. A. et al. The dark side of lipid metabolism in prostate and renal carcinoma: Novel insights into molecular diagnostic and biomarker discovery. Expert Rev. Mol. Diagn. 23, 297–313 (2023).
Gigante, M. et al. miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. J. Transl. Med. 14, 1–13 (2016).
Lucarelli, G. et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. Urol. Oncol. Semin. Orig. Investig. 35(461), e15-461.e27 (2017).
Lucarelli, G. et al. MUC1 expression affects the immunoflogosis in renal cell carcinoma microenvironment through complement system activation and immune infiltrate modulation. Int. J. Mol. Sci. 24, 4814 (2023).
Shi, W. & Siemann, D. W. Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br. J. Cancer 87, 119–126 (2002).
Shapiro, D. D. et al. Understanding the tumor immune microenvironment in renal cell carcinoma. Cancers 15, 2500 (2023).
Majo, S., Courtois, S., Souleyreau, W., Bikfalvi, A. & Auguste, P. Impact of extracellular matrix components to renal cell carcinoma behavior. Front. Oncol. 10, 625 (2020).
Lasorsa, F. et al. Immune checkpoint inhibitors in renal cell carcinoma: Molecular basis and rationale for their use in clinical practice. Biomedicines 11, 1071 (2023).
Lasorsa, F. et al. Cellular and molecular players in the tumor microenvironment of renal cell carcinoma. J. Clin. Med. 12, 3888 (2023).
Ozerlat, I. Kidney cancer: Targeted therapy of glucose uptake via GLUT1 kills RCC cells. Nat. Rev. Urol. 8, 471 (2011).
Perrino, C. M. et al. Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases. Histopathology 72, 305–319 (2018).
Zhao, C. X., Luo, C. L. & Wu, X. H. Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2. Med. Oncol. 32, 1–9 (2015).
Shapiro, D. D., Virumbrales-Muñoz, M., Beebe, D. J. & Abel, E. J. Models of renal cell carcinoma used to investigate molecular mechanisms and develop new therapeutics. Front. Oncol. 12, 871252 (2022).
Lugand, L. et al. Methods for establishing a renal cell carcinoma tumor spheroid model with immune infiltration for immunotherapeutic studies. Front. Oncol. 12, 898732 (2022).
Sobczuk, P. et al. Choosing the right animal model for renal cancer research. Transl. Oncol. 13, 100745 (2020).
Edington, C. D. et al. Interconnected microphysiological systems for quantitative biology and pharmacology studies. Sci. Rep. 8, 4530 (2018).
Caetano-Pinto, P. Amplifying the impact of kidney microphysiological systems: Predicting renal drug clearance using mechanistic modelling based on reconstructed drug secretion. ALTEX https://doi.org/10.14573/altex.2204011 (2022).
Miller, C. P., Tsuchida, C., Zheng, Y., Himmelfarb, J. & Akilesh, S. A 3D human renal cell carcinoma-on-a-chip for the study of tumor angiogenesis. Neoplasia (United States) 20, 610–620 (2018).
Simon, B. R., Wilson, M. J. & Wickliffe, J. K. The RPTEC/TERT1 cell line models key renal cell responses to the environmental toxicants, benzo[a]pyrene and cadmium. Toxicol. Rep. 1, 231–242 (2014).
Tao, T. P. et al. Demonstration of the first-pass metabolism in the skin of the hair dye, 4-amino-2-hydroxytoluene, using the Chip2 skin–liver microphysiological model. J. Appl. Toxicol. 41, 1553–1567 (2021).
Clement, C. A. et al. TGF-β signaling is associated with endocytosis at the pocket region of the primary cilium. Cell Rep. 3, 1806–1814 (2013).
Caetano-Pinto, P. et al. Epidermal growth factor receptor mediates the basolateral uptake of phosphorothioate-modified antisense oligonucleotides in the kidney. Organs-on-a-Chip 4, 100022 (2022).
Leung, C. M. et al. A guide to the organ-on-a-chip. Nat. Rev. Methods Prim. 2, 33 (2022).
Wang, D., Gust, M. & Ferrell, N. Kidney-on-a-chip: Mechanical stimulation and sensor integration. Sensors 22, 6889 (2022).
Padmyastuti, A. et al. Microfluidic-based prostate cancer model for investigating the secretion of prostate-specific antigen and microRNAs in vitro. Sci. Rep. 13, 11623 (2023).
Rougerie, P. et al. Topographical curvature is sufficient to control epithelium elongation. Sci. Rep. 10, 14784 (2020).
van Genderen, A. M. et al. Topographic guidance in melt-electrowritten tubular scaffolds enhances engineered kidney tubule performance. Front. Bioeng. Biotechnol. 8, 617364 (2021).
Kistner, T. M., Pedersen, B. K. & Lieberman, D. E. Interleukin 6 as an energy allocator in muscle tissue. Nat. Metab. 4, 170–179 (2022).
Che, K., Han, W., Zhang, M. & Niu, H. Role of neutrophil gelatinase-associated lipocalin in renal cell carcinoma (review). Oncol. Lett. 21, 1 (2021).
Arena, A. et al. Both IL-1β and TNF-α regulate NGAL expression in polymorphonuclear granulocytes of chronic hemodialysis patients. Mediat. Inflamm. 2010, 613937. https://doi.org/10.1155/2010/613937 (2010).
Li, X. et al. Lactate metabolism in human health and disease. Signal Transduct. Target. Ther. 7, 305 (2022).
Rawls, K. D. et al. Predicting changes in renal metabolism after compound exposure with a genome-scale metabolic model. Toxicol. Appl. Pharmacol. 412, 115390 (2021).
Xiao, C. et al. Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy. Front. Cell Dev. Biol. 10, 1013885 (2022).
Mohamed, E., Al-Khami, A. A. & Rodriguez, P. C. The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates. Cell. Mol. Immunol. 15, 421–427 (2018).
Caetano-Pinto, P. et al. In vitro characterization of renal drug transporter activity in kidney cancer. Int. J. Mol. Sci. 23, 10177 (2022).
Bolon, C., Gauthier, C. & Simonnet, H. Glycolysis inhibition by palmitate in renal cells cultured in a two-chamber system. Am. J. Physiol. Cell Physiol. 273, C1732–C1738 (1997).
Smith, C. P. et al. Proximal tubule transferrin uptake is modulated by cellular iron and mediated by apical membrane megalin–cubilin complex and transferrin receptor 1. J. Biol. Chem. 294, 7025–7036 (2019).
Ewald, M. L., Chen, Y. H., Lee, A. P. & Hughes, C. C. W. The vascular niche in next generation microphysiological systems. Lab Chip 21, 3244–3262 (2021).
Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
Ogura, T., Tsuchiya, A., Minas, T. & Mizuno, S. Methods of high integrity RNA extraction from cell/agarose construct. BMC Res. Notes 8, 1–8 (2015).
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25, 402–408 (2001).
Sedlazeck, F. J., Rescheneder, P. & Von Haeseler, A. NextGenMap: Fast and accurate read mapping in highly polymorphic genomes. Bioinformatics 29, 2790–2791 (2013).
Liao, Y., Smyth, G. K. & Shi, W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 1–21 (2014).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41598-024-60164-w